Neuron23

Neuron23 is a clinical-stage biotechnology company specializing in precision medicines for genetically defined neurological and immunological diseases. They are focused on developing therapeutics using advanced techniques in machine learning and artificial intelligence for neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Their current focus is on NEU-411, a LRRK2 inhibitor for early Parkinson's disease.

Funding Round: Series D

Funding Amount: $96.5M

Date: 24-Jun-2025

Investors: Westlake Village BioPartners, SoftBank Vision Fund 2, Redmile Group, Blue Owl, Kleiner Perkins, HBM Healthcare Investments (Cayman) Ltd., Acorn Bioventures, a healthcare investor

Markets: Biotech, Healthtech, Pharmaceutical

HQ: South San Francisco, California, United States

Founded: 2018

Website: https://www.neuron23.com

LinkedIn: https://www.linkedin.com/company/neuron23-inc/

Twitter: https://x.com/official_N23

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/neuron23

Pitchbook: https://pitchbook.com/profiles/company/265320-91